XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Operating Segments
3 Months Ended
Mar. 31, 2015
Operating Segments [Abstract]  
Operating Segments

Note 8. Operating Segments

 

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

  

  

Three Months Ended

March 31,

 
  2015  2014 
Contract/Grant Revenue      
Vaccines/BioDefense $802,314  $877,045 
BioTherapeutics  13,972   33,552 
Total $816,286  $910,597 
         
Income/(Loss) from Operations        
Vaccines/BioDefense $84,681  $139,404 
BioTherapeutics  (764,876)  (1,035,591)
Corporate  (878,072)  (693,722)
Total $(1,558,267) $(1,589,909)

 

Amortization and Depreciation Expense

        
Vaccines/BioDefense $9,786  $9,935 
BioTherapeutics  48,374   49,939 
Corporate  1,766   2,213 
Total $59,926  $62,087 
         

Interest Income

        
Corporate $561  $291 
         
Share-Based Compensation        
Vaccines/BioDefense $24,592  $10,450 
BioTherapeutics  29,256   76,121 
Corporate  88,177   90,091 
Total $142,025  $176,662 

 

  

As of

March 31,

2015

  As of 
December 31, 
2014
 
       
Identifiable Assets      
Vaccines/BioDefense $568,565  $1,025,220 
BioTherapeutics  161,355   204,308 
Corporate  5,172,737   5,724,720 
Total $5,902,657  $6,954,248